Please assess the completion status of the following clinical trial:

Trial Title: Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent and HIPAA authorization for release of personal health information.~  •≥ 18 years old at the time of informed consent~* Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study.~* Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy.~NOTE: Switching patient from current pain regimen to morphine equivalent for at least 1-2 weeks prior to registration for protocol therapy is required.~* Requiring greater than or equal to 180 mg of morphine per day. See Appendix 1 for Morphine Conversion Calculator.~* Inadequately controlled pain even with the use of morphine (VAS score \>5) See Appendix 8~* Rescue pain medications are allowed this may include the use of NSAIDS or Tylenol as well as morphine IR.~* ECOG Performance Status of 0-2~* Ability to swallow and tolerate oral tablets.~* Patients getting radiation therapy are allowed at the discretion of the treating physician.~* Females of childbearing potential must have a negative pregnancy test NOTE: Females are considered of child bearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal (\> 12 months since last menses).~NOTE: Females using hormonal contraceptives should be switched to non-hormonal forms of contraception.~The following laboratory values must be obtained. Patient with aplastic anemia will be excluded.~* White blood cell count (WBC) ≥ 3.0 K/mm3~* Absolute neutrophil count ≥ 1.5 K/mm3~* Hemoglobin (Hgb) ≥ 9 g/dL~* Platelets ≥ 75 K/mm3~* Creatinine ≤ 1.5 mg/dl~* Bilirubin ≤ 1.5 x ULN~* Aspartate aminotransferase (AST, SGOT) ≤ 3 x ULN~* Alanine aminotransferase (ALT, SGPT) ≤ 3 x ULN~Exclusion Criteria:~• Active central nervous system (CNS) metastases. Patients with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician.~NOTE: Patients with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.~• Concurrent use of adjuvant medication such as but not limited to: gabapentin, pregabalin or duloxetine etc.~NOTE: Patients on gabapentin or pregabalin can be considered if they can be tapered off before enrolling on the study.~* Treatment with any investigational agent within 30 days prior to registration for protocol therapy.~* Patient with rapidly escalating pain that require hospitalization or an intravenous opioid therapy~* Concurrent participation in a clinical trial which involves another investigational agent.~* Concurrent use of medications that are strong CYP3A4 inhibitors within 14 days prior to registration for protocol therapy as Oxcarbazepine is strong CYP3A4 inducer. See Appendix 7.~NOTE: Concurrent use of other CYP3A4 inhibitors may be allowed at the discretion of the treating physician or principal investigator.~* Allergic reaction to carbamazepine or oxcarbazepine (HLA-B1502)~* Allergy or other contraindication to morphine sulphate~* Opiate-induced uncontrolled constipation or bowel obstruction~* Patient who lives alone.~* Female who is pregnant or breastfeeding~* Patient who has a diagnosis of epilepsy and/or is currently taking anti-epileptic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxcarbazepine and Morphine (Type: OTHER): Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).